(Q41066773)

26 September 2017

1 reference

title

Protein glycation in the kidney: role in diabetes and aging (English)

1 reference

26 September 2017

Vlassara H

1

1 reference

26 September 2017

language of work or name

English

0 references

publication date

1 June 1996

1 reference

26 September 2017

1 reference

26 September 2017

volume

49

1 reference

26 September 2017

issue

6

1 reference

26 September 2017

page(s)

1795-1804

1 reference

Diabetic nephropathy: pathogenesis and treatment

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Advanced glycosylation end products in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleu

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Chemistry of collagen cross-links: glucose-mediated covalent cross-linking of type-IV collagen in lens capsules

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Production and characterization of antibodies to advanced glycation products on proteins

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aging reduces venous distensibility and the venodilatory response to nitroglycerin in normal subjects

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Lipid advanced glycosylation: pathway for lipid oxidation in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Hemoglobin-AGE: a circulating marker of advanced glycosylation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Long-term assessment of glucose control by haemoglobin-AGE measurement

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.270

7 January 2021

Identifiers

DOI

10.1038/KI.1996.270

1 reference

26 September 2017

1 reference